{
  "docId": "019de070-182a-72ba-952e-2b048c610e12",
  "docSlug": "cea7bfa85dc209a87c7b2adf6cd4697f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 22 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 22,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "The slide outlines a multi-cohort trial structure transitioning from IV to SC administration.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-182a-72ba-952e-2b048c610e12/20",
  "deckHref": "/decks/019de070-182a-72ba-952e-2b048c610e12",
  "deckJsonHref": "/decks/019de070-182a-72ba-952e-2b048c610e12.json",
  "deckAnchorHref": "/decks/019de070-182a-72ba-952e-2b048c610e12#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.68,
        "x": 0.27,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Cohort progression from Part 1 (IV) to Part 2 (SC)",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4462eb92-4b69-4fa2-ba69-cf2123437090",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.43,
        "w": 0.24,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "framework",
      "text": "Key Inclusion Criteria and Endpoints",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a9c14df-192c-4687-a6d6-67d7c9809426",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.638,
        "x": 0.344,
        "y": 0.658
      },
      "kind": "paragraph",
      "text": "Company announced CTA approval by UK's MHRA in April 2020. Preparing to initiate the trial in 2Q2020",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c5e8fac-3c36-44a2-b3cf-42793f957838",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.55,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "Dose dependent reduction in tHcy establishes proof of concept",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8a2eed3-0743-4999-82db-3a915ec5ac96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "ACN00177 for Homocystinuria – Phase 1/2 Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2f63e2b-eaf2-4c06-8a5d-250178688756",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "2d94d965-7458-4b9f-90f6-7889d53f6769",
      "evidence": "Structured bullet points for criteria and endpoints",
      "confidence": 0.9
    },
    {
      "name": "timeline",
      "slug": null,
      "matchId": "3e9adaae-cda5-4f84-b237-7c4b4a5c8167",
      "evidence": "Sequential cohort progression diagram",
      "confidence": 0.95
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}